Profiling cancer gene mutations in clinical formalin-fixed, paraffin-embedded colorectal tumor specimens using targeted next-generation sequencing.
暂无分享,去创建一个
G. Hampton | P. Hegde | W. Forrest | H. Koeppen | M. Lackner | Sachin Sah | S. Jia | Liangjing Chen | Rajesh Patel | R. Raja | Liangxuan Zhang | Liangjing Chen | Sachin Sah | Gary J Latham | Rajesh Patel | Qinghua Song | Hartmut Koeppen | Rachel Tam | Erica Schleifman | Haider Mashhedi | Sreedevi Chalasani | Ling Fu | Teiko Sumiyoshi | Rajiv Raja | William Forrest | Garret M Hampton | Mark R Lackner | Priti Hegde | Shidong Jia | G. Latham | S. Chalasani | L. Fu | Qinghua Song | E. Schleifman | Liangxuan Zhang | Rachel N. Tam | T. Sumiyoshi | H. Mashhedi | Sreedevi Chalasani
[1] M. Lackner. Prospects for personalized medicine with inhibitors targeting the RAS and PI3K pathways , 2010, Expert review of molecular diagnostics.
[2] T. Roberts,et al. Should individual PI3 kinase isoforms be targeted in cancer? , 2009, Current opinion in cell biology.
[3] Ashish Choudhary,et al. Targeted, high-depth, next-generation sequencing of cancer genes in formalin-fixed, paraffin-embedded and fine-needle aspiration tumor specimens. , 2013, The Journal of molecular diagnostics : JMD.
[4] J. Leamon,et al. Combining highly multiplexed PCR with semiconductor-based sequencing for rapid cancer genotyping. , 2013, The Journal of molecular diagnostics : JMD.
[5] M. Loda,et al. Opposing effects of androgen deprivation and targeted therapy on prostate cancer prevention. , 2013, Cancer discovery.
[6] G. Hampton,et al. Prostate cancer – a biomarker perspective , 2012, Front. Endocrin..
[7] Rajesh Patel,et al. Mutation Scanning Using MUT-MAP, a High-Throughput, Microfluidic Chip-Based, Multi-Analyte Panel , 2012, PloS one.
[8] G. Hampton,et al. Phosphoinositide 3-Kinase (PI3K) Pathway Alterations Are Associated with Histologic Subtypes and Are Predictive of Sensitivity to PI3K Inhibitors in Lung Cancer Preclinical Models , 2012, Clinical Cancer Research.
[9] Satoshi Matsumoto,et al. Frequent somatic mutations in PTEN and TP53 are mutually exclusive in the stroma of breast carcinomas , 2002, Nature Genetics.
[10] Hans E. Huber,et al. Breast Tumor Cells with PI3K Mutation or HER2 Amplification Are Selectively Addicted to Akt Signaling , 2008, PloS one.
[11] N. Ilić,et al. Comparing the roles of the p110α and p110β isoforms of PI3K in signaling and cancer. , 2010, Current topics in microbiology and immunology.
[12] H. Swerdlow,et al. A tale of three next generation sequencing platforms: comparison of Ion Torrent, Pacific Biosciences and Illumina MiSeq sequencers , 2012, BMC Genomics.
[13] Rashmi Kanagal-Shamanna,et al. Clinical validation of a next-generation sequencing screen for mutational hotspots in 46 cancer-related genes. , 2013, The Journal of molecular diagnostics : JMD.
[14] Steven J. M. Jones,et al. Comprehensive molecular characterization of human colon and rectal cancer , 2012, Nature.
[15] A. Burden,et al. A germline mutation in KIT in familial diffuse cutaneous mastocytosis , 2004, Journal of Medical Genetics.
[16] L. Beckett,et al. Algorithm for codevelopment of new drug-predictive biomarker combinations: accounting for inter- and intrapatient tumor heterogeneity. , 2012, Clinical lung cancer.
[17] Jing Zhang,et al. Targeting PI3K signaling as a therapeutic approach for colorectal cancer. , 2011, Gastroenterology.
[18] Richard W Tothill,et al. Next-generation sequencing for cancer diagnostics: a practical perspective. , 2011, The Clinical biochemist. Reviews.
[19] L. Schmidt,et al. A novel germ line juxtamembrane Met mutation in human gastric cancer , 2000, Oncogene.
[20] Quentin Liu,et al. Targeted therapy: tailoring cancer treatment , 2013, Chinese journal of cancer.
[21] S. Aggarwal. Targeted cancer therapies , 2010, Nature Reviews Drug Discovery.
[22] J. Tabernero,et al. Development of PI3K inhibitors: lessons learned from early clinical trials , 2013, Nature Reviews Clinical Oncology.